Jian Zhang1, Linhai Xiao2, Shengyu Pu1, Yang Liu1, Jianjun He3, Ke Wang4. 1. Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an, 710061, China. 2. School of Public Health, Fudan University, No. 130 Dong'an Road, Shanghai, 200032, China. 3. Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an, 710061, China. chinahjj@163.com. 4. Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 Yanta West Road, Xi'an, 710061, China. xjtu_wet@163.com.
Abstract
BACKGROUND: Pathological responses of neoadjuvant chemotherapy (NCT) are associated with survival outcomes in patients with breast cancer. Previous studies constructed models using out-of-date variables to predict pathological outcomes, and lacked external validation, making them unsuitable to guide current clinical practice. OBJECTIVE: The aim of this study was to develop and validate a nomogram to predict the objective remission rate (ORR) of NCT based on pretreatment clinicopathological variables. METHODS: Data from 110 patients with breast cancer who received NCT were used to establish and calibrate a nomogram for pathological outcomes based on multivariate logistic regression. The predictive performance of this model was further validated using a second cohort of 55 patients with breast cancer. Discrimination of the prediction model was assessed using an area under the receiver operating characteristic curve (AUC), and calibration was assessed using calibration plots. The diagnostic odds ratio (DOR) was calculated to further evaluate the performance of the nomogram and determine the optimal cut-off value. RESULTS: The final multivariate regression model included age, NCT cycles, estrogen receptor, human epidermal growth factor receptor 2 (HER2), and lymphovascular invasion. A nomogram was developed as a graphical representation of the model and showed good calibration and discrimination in both sets (an AUC of 0.864 and 0.750 for the training and validation cohorts, respectively). Finally, according to the Youden index and DORs, we assigned an optimal ORR cut-off value of 0.646. CONCLUSION: We developed a nomogram to predict the ORR of NCT in patients with breast cancer. Using the nomogram, for patients who are operable and whose ORR is < 0.646, we believe that the benefits of NCT are limited and these patients can be treated directly using surgery.
BACKGROUND: Pathological responses of neoadjuvant chemotherapy (NCT) are associated with survival outcomes in patients with breast cancer. Previous studies constructed models using out-of-date variables to predict pathological outcomes, and lacked external validation, making them unsuitable to guide current clinical practice. OBJECTIVE: The aim of this study was to develop and validate a nomogram to predict the objective remission rate (ORR) of NCT based on pretreatment clinicopathological variables. METHODS: Data from 110 patients with breast cancer who received NCT were used to establish and calibrate a nomogram for pathological outcomes based on multivariate logistic regression. The predictive performance of this model was further validated using a second cohort of 55 patients with breast cancer. Discrimination of the prediction model was assessed using an area under the receiver operating characteristic curve (AUC), and calibration was assessed using calibration plots. The diagnostic odds ratio (DOR) was calculated to further evaluate the performance of the nomogram and determine the optimal cut-off value. RESULTS: The final multivariate regression model included age, NCT cycles, estrogen receptor, humanepidermal growth factor receptor 2 (HER2), and lymphovascular invasion. A nomogram was developed as a graphical representation of the model and showed good calibration and discrimination in both sets (an AUC of 0.864 and 0.750 for the training and validation cohorts, respectively). Finally, according to the Youden index and DORs, we assigned an optimal ORR cut-off value of 0.646. CONCLUSION: We developed a nomogram to predict the ORR of NCT in patients with breast cancer. Using the nomogram, for patients who are operable and whose ORR is < 0.646, we believe that the benefits of NCT are limited and these patients can be treated directly using surgery.
Authors: Sara A Hurvitz; Miguel Martin; W Fraser Symmans; Kyung Hae Jung; Chiun-Sheng Huang; Alastair M Thompson; Nadia Harbeck; Vicente Valero; Daniil Stroyakovskiy; Hans Wildiers; Mario Campone; Jean-François Boileau; Matthias W Beckmann; Karen Afenjar; Rodrigo Fresco; Hans-Joachim Helms; Jin Xu; Yvonne G Lin; Joseph Sparano; Dennis Slamon Journal: Lancet Oncol Date: 2017-11-23 Impact factor: 41.316
Authors: M Takada; M Sugimoto; S Ohno; K Kuroi; N Sato; H Bando; N Masuda; H Iwata; M Kondo; H Sasano; L W C Chow; T Inamoto; Y Naito; M Tomita; M Toi Journal: Breast Cancer Res Treat Date: 2012-06-12 Impact factor: 4.872
Authors: Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz Journal: Lancet Date: 2014-02-14 Impact factor: 79.321
Authors: M Colleoni; G Viale; D Zahrieh; L Bottiglieri; R D Gelber; P Veronesi; A Balduzzi; R Torrisi; A Luini; M Intra; S Dellapasqua; A Cardillo; R Ghisini; G Peruzzotti; A Goldhirsch Journal: Ann Oncol Date: 2007-11-06 Impact factor: 32.976
Authors: Mehra Golshan; Constance T Cirrincione; William M Sikov; Donald A Berry; Sara Jasinski; Tracey F Weisberg; George Somlo; Clifford Hudis; Eric Winer; David W Ollila Journal: Ann Surg Date: 2015-09 Impact factor: 12.969